This study is testing a new medicine called depemokimab to see if it helps people with Chronic Obstructive Pulmonary Disease (COPD), a lung disease that makes it hard to breathe. The study is for people aged 40 to 80 who have moderate to severe COPD and have a type of inflammation called Type 2 inflammation. Participants should have a history of smoking and are already on certain inhaler treatments. Eosinophils are a type of white blood cell, and participants need to have an elevated count of these cells in their blood.

• The study requires participants to be on existing inhaler therapy for at least 6 months before starting.
• Participants should not have other lung diseases like asthma or need more than 12 hours of oxygen daily.
• Individuals will be checked for their health status and history of lung infections before joining.

This study will help us understand if depemokimab can be a safe and effective treatment for managing symptoms of COPD. Participants will be closely monitored to ensure their safety and the effectiveness of the treatment.